News
- Details
On June 4, Alexey Orlov, First Deputy Governor of the Sverdlovsk Region, inspected a new medical mask workshop at the Medsintez plant, the largest pharmaceutical manufacturer in the Middle Urals.
- Details
On May 15, 2020, the Academic Board of the Ural State Medical University approved the instructional guidelines “On Using Triazavirin in Terms of Treatment and Post-Exposure Prophylaxis for the New Coronavirus Infection, COVID-19”.
- Details
- Details
Leading Russian scientists and clinicians included Triazavirin, the antiviral drug, in the interim “Drug treatment for acute respiratory viral infections (ARVI) in outpatient practices during the COVID-19 epidemic” guidelines. The guidelines on ARVI drug treatment have been posted on the website of the Ministry of Health of Russia and sent to Russian regions for reference of outpatient service doctors who deal with outpatients showing signs of ARVI.
- Details
The Ministry of Health of the Russian Federation has registered a new drug, Primapur®, a recombinant follicle-stimulating hormone (FSH), which has been designed to treat human infertility and is now produced at the Medsintez plant. A fully Russian drug; it went through all stages, from the development and creation of a pharmaceutical substance to the release of a finished dosage form, exclusively in the Russian Federation. In 2019, the Medsintez plant produced four series of the FSH pharmaceutical substance and released the first four commercial batches of Primapur® finished dosage forms, which will reach clinics in early 2020.
Torgovaya 15, Novouralsk, Sverdlovsk region, Russia, 624130